In-silico design, synthesis and biological evaluation of 4-aryl-4H-chromene derivatives as CDK-2 inhibitors: A molecular approach to finding a lead for breast cancer

Sk Md Sohail Amin, Prajakta Harish Patil, Mrunal Desai, Jagadish Puralae Channabasavaiah

Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India.

Doi: http://dx.doi.org/10.7324/JAPS.2024.155052

SUPPLEMENTARY MATERIAL

IN-SILICO DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-4H-CHROMENE DERIVATIVES AS CDK-2 INHIBITORS: A MOLECULAR APPROACH TO FINDING A LEAD FOR BREAST CANCER

Below are the spectral data’s containing IR, MS and ^1^HNMR for the six synthesized compounds, including 2C, 2N, 2J, 2P, 2F and 1L.
Figure S1. Spectral data of compound 2C: (A) IR, (B) MS, (C) $^1$HNMR.
Figure S2. Spectral data of compound 2N: (A) IR, (B) MS, (C) $^1$HNMR.
Figure S3. Spectral data of compound 2J: (A) IR, (B) MS, (C) ^1^HNMR.
Figure S4. Spectral data of compound 2P: (A) IR, (B) MS, (C) $^1$H NMR.
Figure S5. Spectral data of compound 2F: (A) IR, (B) MS, (C) $^1$H NMR.
Figure S6. Spectral data of compound 1L: (A) IR, (B) MS, (C) $^1$HNMR.
Figure S7. SRB assay in MCF-7 cell lines: Control group

Figure S8. SRB assay in MCF-7 cell lines: Group treated with 1L
Figure S9. SRB assay in MCF-7 cell lines: Group treated with 2O

Figure S10. SRB assay in MCF-7 cell lines: Group treated with 2K
Figure S11. SRB assay in MCF-7 cell lines: Group treated with 1C